Gaois

Search direction

Search mode

Filter results

Collections

4 results in 1 document

  1. #2694334

    An 17 Márta 2020, rinne an t-iarratasóir iarraidh ar an gCoimisiún freisin ar chosaint staidéir eolaíocha agus sonraí dílseánaigh a cuireadh isteach chun tacú leis an iarratas, is iad sin, bailíochtú modhanna na mais-speictriméadrachta (“MS”,) an athshondais mhaighnéadaigh núicléach (“AMN”) agus na crómatagrafaíochta ainianmhalartúcháin ardfheidhmíochta le haimpéarméadrach bíogach braite (“HPAEC-PAD”) agus na torthaí maidir le aitheantas 3-FL agus fotháirgí carbaihiodráite a chinneadh; tuairisc ar thréithchineál táirgthe 3-FL géinmhodhnaithe; deimhniú deascaidh thréithchineál táirgthe 3-FL géinmhodhnaithe; córas imoibriú slabhrúil polaiméaráise cúl-trascrioptáise cainníochtúil fíor-ama (“qPCR”) agus tuarascálacha bailíochtaithe modha maidir le tréithchineál táirgthe 3-FL géinmhodhnaithe; tástáil bhaictéarach ais-sócháin le 3-FL; tástáil micreanúicléis in vitro i gcealla mamach le 3-FL; staidéar raoin dáileoige 7 lá ar thocsaineacht bhéil i bhfrancaigh le 3-FL; agus staidéar 90 lá ar thocsaineacht bhéil i bhfrancaigh le 3-FL.

    On 17 March 2020, the applicant also made a request to the Commission for the protection of proprietary scientific studies and data submitted in support of the application, namely, the mass spectrometry (‘MS’), nuclear magnetic resonance (‘NMR’) spectroscopy and high-performance anion-exchange chromatography with pulsed amperometric detection (‘HPAEC-PAD’) method validation and the results for the determination of the identity of 3-FL and carbohydrate by-products; a description of the genetically modified 3-FL production strain; a certificate of deposition of the genetically modified 3-FL production strain; real time quantitative polymerase chain reaction (‘qPCR’) system and method validation reports for the genetically modified 3-FL production strain; a bacterial reverse mutation test with 3-FL; an in vitro mammalian cell micronucleus test with 3-FL; a 7-day dose range finding oral toxicity study in rats with 3-FL; and, a 90-day oral toxicity study in rats with 3-FL.

    Commission Implementing Regulation (EU) 2023/52 of 4 January 2023 authorising the placing on the market of 3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21(DE3) as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)

  2. #2694339

    Sa tuairim eolaíoch uaidh, mheas an tÚdarás nach bhféadfadh sé teacht ar a chonclúidí maidir le sábháilteacht 3-FL gan na staidéir agus na sonraí eolaíocha ar bhailíochtú modha MS, NMR agus HPAEC-PAD agus na torthaí maidir le haitheantas 3-FL agus na seachtháirgí carbaihiodráite atá sa bhia núíosach a chinneadh; an tuairisc ar thréithchineál táirgthe 3-FL géinmhodhnaithe; deimhniú deascaidh thréithchineál táirgthe ghéinmhodhnaithe 3-fúcaishiollachtóis; an córas qPCR agus an tuarascáil bhailíochtaithe modha maidir le tréithchineál táirgthe géinmhodhnaithe 3-FL; an tástáil bhaictéarach ais-sócháin le 3-FL; an tástáil micreanúicléis in vitro i gcealla mamach le 3-FL; staidéar raoin dáileoige 7 lá ar thocsaineacht bhéil i bhfrancaigh le 3-F; agus, an staidéar 90 lá ar thocsaineacht bhéil i bhfrancaigh le 3-FL.

    In its scientific opinion, the Authority considered that it could not have reached its conclusions on the safety of the 3-FL without the scientific studies and data on the MS, NMR and HPAEC-PAD method validation and the results for the determination of the identity of 3-FL and of the carbohydrate by-products present in the novel food; the description of the genetically modified 3-FL production strain; the certificate of deposition of the genetically modified 3-fucosyllactose production strain; the qPCR system and method validation report for the genetically modified 3-FL production strain; the bacterial reverse mutation test with 3-FL; the in vitro mammalian cell micronucleus test with 3-FL; the 7-day dose range finding oral toxicity study in rats with 3-FL; and, the 90-day oral toxicity study in rats with 3-FL.

    Commission Implementing Regulation (EU) 2023/52 of 4 January 2023 authorising the placing on the market of 3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21(DE3) as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)

  3. #2694341

    Dhearbhaigh an t-iarratasóir go raibh cearta dílseánaigh agus eisiacha aige chun tagairt a dhéanamh do na staidéir agus na sonraí eolaíocha i dtaca le bailíochtú modha MS, NMR agus HPAEC-PAD agus leis na torthaí maidir le haitheantas 3-FL agus na seachtháirgí carbaihiodráite atá sa bhia núíosach a chinneadh; an tuairisc ar thréithchineál táirgthe 3-FL géinmhodhnaithe; deimhniú deascaidh an tréithchineáil táirgthe ghéinmhodhnaithe 3-FL; an córas qPCR agus an tuarascáil bhailíochtaithe modha maidir le tréithchineál táirgthe géinmhodhnaithe 3-FL; an tástáil bhaictéarach ais-sócháin le 3-FL; an tástáil micreanúicléis in vitro i gcealla mamach le 3-FL; staidéar raoin dáileoige 7 lá ar thocsaineacht bhéil i bhfrancaigh le 3-F; agus, an staidéar 90 lá ar thocsaineacht bhéil i bhfrancaigh le 3-FL, faoin dlí náisiúnta an tráth a chuir sé an t-iarratas isteach, agus nach féidir le tríú páirtithe rochtain dhlíthiúil a fháil ar na sonraí ná na staidéir sin, iad a úsáid ná tagairt a dhéanamh dóibh.

    The applicant declared that they held proprietary and exclusive rights of reference to the scientific studies and data on MS, NMR and HPAEC-PAD method validation and the results for the determination of the identity of 3-FL and of the carbohydrate by-products present in the novel food; the description of the genetically modified 3-FL production strain; the certificate of deposition of the genetically modified 3-FL production strain; the qPCR system and method validation report for the genetically modified 3-FL production strain; the bacterial reverse mutation test with 3-FL; the in vitro mammalian cell micronucleus test with 3-FL; the 7-day dose range finding oral toxicity study in rats with 3-FL; and, the 90-day oral toxicity study in rats with 3-FL, under national law at the time they submitted the application, and that third parties cannot lawfully access, use or refer to those data and studies.

    Commission Implementing Regulation (EU) 2023/52 of 4 January 2023 authorising the placing on the market of 3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21(DE3) as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)

  4. #2694343

    Dá bhrí sin, na staidéir agus na sonraí eolaíocha ar bhailíochtú modha MS, NMR agus HPAEC-PAD agus na torthaí maidir le haitheantas 3-FL agus na seachtháirgí carbaihiodráite atá sa bhia núíosach a chinneadh; an tuairisc ar thréithchineál táirgthe 3-FL géinmhodhnaithe; deimhniú deascaidh an tréithchineáil táirgthe ghéinmhodhnaithe 3-FL; an córas qPCR agus an tuarascáil bhailíochtaithe modha maidir le tréithchineál táirgthe géinmhodhnaithe 3-FL; an tástáil bhaictéarach ais-sócháin le 3-FL; an tástáil micreanúicléis in vitro i gcealla mamach le 3-FL; staidéar raoin dáileoige 7 lá ar thocsaineacht bhéil i bhfrancaigh le 3-F; agus, an staidéar 90 lá ar thocsaineacht bhéil i bhfrancaigh le 3-FL, ba cheart iad a chosaint i gcomhréir le hAirteagal 27(1) de Rialachán (AE) 2015/2283.

    Therefore, the scientific studies and data on MS, NMR and HPAEC-PAD method validation and the results for the determination of the identity of 3-FL and of the carbohydrate by-products present in the novel food; the description of the genetically modified 3-FL production strain; the certificate of deposition of the genetically modified 3-FL production strain; the qPCR system and method validation report for the genetically modified 3-FL production strain; the bacterial reverse mutation test with 3-FL; the in vitro mammalian cell micronucleus test with 3-FL; the 7-day dose range finding oral toxicity study in the rat with 3-FL; and, the 90-day oral toxicity study in the rat with 3-FL, should be protected in accordance with Article 27(1) of Regulation (EU) 2015/2283.

    Commission Implementing Regulation (EU) 2023/52 of 4 January 2023 authorising the placing on the market of 3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21(DE3) as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)